129-LB: Similar Efficacy, Safety, and Immunogenicity in People with Diabetes Using SAR341402 or Insulin Aspart: Gemelli 1 Study
SAR341402 (SAR-Asp) was developed as a biosimilar/follow-on product to rapid-acting insulin NovoLog®/NovoRapid® (NN-Asp). This 6-month randomized, controlled, open-label, phase 3 study compared efficacy and safety of SAR-Asp and NN-Asp in adults with type 1 diabetes (T1D) or type 2 diabetes (T2D) al...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 68 |
| creator | GARG, SATISH K. WERNICKE-PANTEN, KARIN WARDECKI, MAREK KRAMER, DANIEL DELALANDE, FRANCOIS SHAH, VIRAL N. FRANEK, EDWARD SADEHARJU, KARITA MONCHAMP, TRAVIS |
| description | SAR341402 (SAR-Asp) was developed as a biosimilar/follow-on product to rapid-acting insulin NovoLog®/NovoRapid® (NN-Asp).
This 6-month randomized, controlled, open-label, phase 3 study compared efficacy and safety of SAR-Asp and NN-Asp in adults with type 1 diabetes (T1D) or type 2 diabetes (T2D) also using insulin glargine (GLA100) as basal insulin. In total 597 adults with diabetes were randomized (1:1; 497 with T1D, 100 with T2D) to a multiple daily injection regimen of SAR-Asp or NN-Asp along with using once daily GLA100. Glucose targets levels were |
| doi_str_mv | 10.2337/db19-129-LB |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_2337_db19_129_LB</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2337_db19_129_LB</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_2337_db19_129_LB3</originalsourceid><addsrcrecordid>eNqVj7tOwzAYRi0EEuEy8QL_DgZfKiJ3a6FApQ6IgMRmuYldfuQ4ke0IZeLVSQUvgL7hLGf4DiEXnF0LKcubZssV5ULRzfKAFFxJRaUo3w9JwRgXlJeqPCYnKX0yxm6nFeT7155DhS16E2HlHNamHq-gMs7miSY0sG7bIXQ7G7DGPAIGeLZd7y18Yf6AezRbm22Ct4RhB9XiRc74jAnoIqxDGvzkL1JvYp7Do22t9wgcqjw04xk5csYne_7HU3L5sHq9e6J17FKK1uk-YmviqDnT-0a9b9TTa71Zyv_ZP4CzVxE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>129-LB: Similar Efficacy, Safety, and Immunogenicity in People with Diabetes Using SAR341402 or Insulin Aspart: Gemelli 1 Study</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>GARG, SATISH K. ; WERNICKE-PANTEN, KARIN ; WARDECKI, MAREK ; KRAMER, DANIEL ; DELALANDE, FRANCOIS ; SHAH, VIRAL N. ; FRANEK, EDWARD ; SADEHARJU, KARITA ; MONCHAMP, TRAVIS</creator><creatorcontrib>GARG, SATISH K. ; WERNICKE-PANTEN, KARIN ; WARDECKI, MAREK ; KRAMER, DANIEL ; DELALANDE, FRANCOIS ; SHAH, VIRAL N. ; FRANEK, EDWARD ; SADEHARJU, KARITA ; MONCHAMP, TRAVIS</creatorcontrib><description>SAR341402 (SAR-Asp) was developed as a biosimilar/follow-on product to rapid-acting insulin NovoLog®/NovoRapid® (NN-Asp).
This 6-month randomized, controlled, open-label, phase 3 study compared efficacy and safety of SAR-Asp and NN-Asp in adults with type 1 diabetes (T1D) or type 2 diabetes (T2D) also using insulin glargine (GLA100) as basal insulin. In total 597 adults with diabetes were randomized (1:1; 497 with T1D, 100 with T2D) to a multiple daily injection regimen of SAR-Asp or NN-Asp along with using once daily GLA100. Glucose targets levels were <180 mg/dL (2h-postprandial) and 80-130 mg/dL (fasting and pre-prandial) while avoiding hypoglycemia. Primary endpoint was HbA1c change (non-inferiority margin of 0.3%) from baseline to week 26 (tested for non-inferiority of SAR-Asp vs. NN-Asp). Immunogenicity was assessed by anti-insulin aspart antibody (AIA) status (positive/negative) and titers during the study.
SAR-Asp was non-inferior to NN-Asp for change in HbA1c, with similar insulin dosages. There was no difference in the percentage of patients reporting hypoglycaemia. Immunogenicity and safety profiles (adverse events, hypersensitivity events and injection site reactions) were similar for SAR-Asp and NN-Asp (Table).
We conclude that biosimilar/follow-on SAR-Asp is safe, effective and well-tolerated as insulin aspart in adults with T1D or T2D.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db19-129-LB</identifier><language>eng</language><ispartof>Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>GARG, SATISH K.</creatorcontrib><creatorcontrib>WERNICKE-PANTEN, KARIN</creatorcontrib><creatorcontrib>WARDECKI, MAREK</creatorcontrib><creatorcontrib>KRAMER, DANIEL</creatorcontrib><creatorcontrib>DELALANDE, FRANCOIS</creatorcontrib><creatorcontrib>SHAH, VIRAL N.</creatorcontrib><creatorcontrib>FRANEK, EDWARD</creatorcontrib><creatorcontrib>SADEHARJU, KARITA</creatorcontrib><creatorcontrib>MONCHAMP, TRAVIS</creatorcontrib><title>129-LB: Similar Efficacy, Safety, and Immunogenicity in People with Diabetes Using SAR341402 or Insulin Aspart: Gemelli 1 Study</title><title>Diabetes (New York, N.Y.)</title><description>SAR341402 (SAR-Asp) was developed as a biosimilar/follow-on product to rapid-acting insulin NovoLog®/NovoRapid® (NN-Asp).
This 6-month randomized, controlled, open-label, phase 3 study compared efficacy and safety of SAR-Asp and NN-Asp in adults with type 1 diabetes (T1D) or type 2 diabetes (T2D) also using insulin glargine (GLA100) as basal insulin. In total 597 adults with diabetes were randomized (1:1; 497 with T1D, 100 with T2D) to a multiple daily injection regimen of SAR-Asp or NN-Asp along with using once daily GLA100. Glucose targets levels were <180 mg/dL (2h-postprandial) and 80-130 mg/dL (fasting and pre-prandial) while avoiding hypoglycemia. Primary endpoint was HbA1c change (non-inferiority margin of 0.3%) from baseline to week 26 (tested for non-inferiority of SAR-Asp vs. NN-Asp). Immunogenicity was assessed by anti-insulin aspart antibody (AIA) status (positive/negative) and titers during the study.
SAR-Asp was non-inferior to NN-Asp for change in HbA1c, with similar insulin dosages. There was no difference in the percentage of patients reporting hypoglycaemia. Immunogenicity and safety profiles (adverse events, hypersensitivity events and injection site reactions) were similar for SAR-Asp and NN-Asp (Table).
We conclude that biosimilar/follow-on SAR-Asp is safe, effective and well-tolerated as insulin aspart in adults with T1D or T2D.</description><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqVj7tOwzAYRi0EEuEy8QL_DgZfKiJ3a6FApQ6IgMRmuYldfuQ4ke0IZeLVSQUvgL7hLGf4DiEXnF0LKcubZssV5ULRzfKAFFxJRaUo3w9JwRgXlJeqPCYnKX0yxm6nFeT7155DhS16E2HlHNamHq-gMs7miSY0sG7bIXQ7G7DGPAIGeLZd7y18Yf6AezRbm22Ct4RhB9XiRc74jAnoIqxDGvzkL1JvYp7Do22t9wgcqjw04xk5csYne_7HU3L5sHq9e6J17FKK1uk-YmviqDnT-0a9b9TTa71Zyv_ZP4CzVxE</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>GARG, SATISH K.</creator><creator>WERNICKE-PANTEN, KARIN</creator><creator>WARDECKI, MAREK</creator><creator>KRAMER, DANIEL</creator><creator>DELALANDE, FRANCOIS</creator><creator>SHAH, VIRAL N.</creator><creator>FRANEK, EDWARD</creator><creator>SADEHARJU, KARITA</creator><creator>MONCHAMP, TRAVIS</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20190601</creationdate><title>129-LB: Similar Efficacy, Safety, and Immunogenicity in People with Diabetes Using SAR341402 or Insulin Aspart: Gemelli 1 Study</title><author>GARG, SATISH K. ; WERNICKE-PANTEN, KARIN ; WARDECKI, MAREK ; KRAMER, DANIEL ; DELALANDE, FRANCOIS ; SHAH, VIRAL N. ; FRANEK, EDWARD ; SADEHARJU, KARITA ; MONCHAMP, TRAVIS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_2337_db19_129_LB3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GARG, SATISH K.</creatorcontrib><creatorcontrib>WERNICKE-PANTEN, KARIN</creatorcontrib><creatorcontrib>WARDECKI, MAREK</creatorcontrib><creatorcontrib>KRAMER, DANIEL</creatorcontrib><creatorcontrib>DELALANDE, FRANCOIS</creatorcontrib><creatorcontrib>SHAH, VIRAL N.</creatorcontrib><creatorcontrib>FRANEK, EDWARD</creatorcontrib><creatorcontrib>SADEHARJU, KARITA</creatorcontrib><creatorcontrib>MONCHAMP, TRAVIS</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GARG, SATISH K.</au><au>WERNICKE-PANTEN, KARIN</au><au>WARDECKI, MAREK</au><au>KRAMER, DANIEL</au><au>DELALANDE, FRANCOIS</au><au>SHAH, VIRAL N.</au><au>FRANEK, EDWARD</au><au>SADEHARJU, KARITA</au><au>MONCHAMP, TRAVIS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>129-LB: Similar Efficacy, Safety, and Immunogenicity in People with Diabetes Using SAR341402 or Insulin Aspart: Gemelli 1 Study</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2019-06-01</date><risdate>2019</risdate><volume>68</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>SAR341402 (SAR-Asp) was developed as a biosimilar/follow-on product to rapid-acting insulin NovoLog®/NovoRapid® (NN-Asp).
This 6-month randomized, controlled, open-label, phase 3 study compared efficacy and safety of SAR-Asp and NN-Asp in adults with type 1 diabetes (T1D) or type 2 diabetes (T2D) also using insulin glargine (GLA100) as basal insulin. In total 597 adults with diabetes were randomized (1:1; 497 with T1D, 100 with T2D) to a multiple daily injection regimen of SAR-Asp or NN-Asp along with using once daily GLA100. Glucose targets levels were <180 mg/dL (2h-postprandial) and 80-130 mg/dL (fasting and pre-prandial) while avoiding hypoglycemia. Primary endpoint was HbA1c change (non-inferiority margin of 0.3%) from baseline to week 26 (tested for non-inferiority of SAR-Asp vs. NN-Asp). Immunogenicity was assessed by anti-insulin aspart antibody (AIA) status (positive/negative) and titers during the study.
SAR-Asp was non-inferior to NN-Asp for change in HbA1c, with similar insulin dosages. There was no difference in the percentage of patients reporting hypoglycaemia. Immunogenicity and safety profiles (adverse events, hypersensitivity events and injection site reactions) were similar for SAR-Asp and NN-Asp (Table).
We conclude that biosimilar/follow-on SAR-Asp is safe, effective and well-tolerated as insulin aspart in adults with T1D or T2D.</abstract><doi>10.2337/db19-129-LB</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_crossref_primary_10_2337_db19_129_LB |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| title | 129-LB: Similar Efficacy, Safety, and Immunogenicity in People with Diabetes Using SAR341402 or Insulin Aspart: Gemelli 1 Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T07%3A51%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=129-LB:%20Similar%20Efficacy,%20Safety,%20and%20Immunogenicity%20in%20People%20with%20Diabetes%20Using%20SAR341402%20or%20Insulin%20Aspart:%20Gemelli%201%20Study&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=GARG,%20SATISH%20K.&rft.date=2019-06-01&rft.volume=68&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db19-129-LB&rft_dat=%3Ccrossref%3E10_2337_db19_129_LB%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |